ReviewJournal of ophthalmology2026
Long-Term Graft Survival and Visual Outcomes in Deep Anterior Lamellar Keratoplasty (DALK): A Narrative Review.
Review in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Graft Survival and Visual Outcomes in Deep Anterior Lamellar Keratoplasty (DALK): A Narrative Review.Journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep anterior lamellar keratoplasty (DALK) selectively replaces the scarred or diseased corneal stroma, while preserving healthy endothelium, thus providing an alternative to penetrating keratoplasty (PK) for patients with stromal disorders. Despite its recognized advantages, DALK has not become as widely adopted as anticipated over the past decades. The satisfactory visual outcomes of PK, the lack of standardized DALK techniques, as well as the limited long-term data on visual and refractive outcomes for both DALK and PK are commonly cited as barriers to its broader implementation. Evidence from long-term studies indicates that DALK offers superior graft survival and provides a safer intraoperative profile with fewer complications and lower endothelial cell loss, making it the preferred option for stromal diseases with healthy endothelium.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.